Search

Simple Summary: Acute lymphoblastic leukemia (ALL) is a hematological disease characterized by the malfunction of the hematopoietic system. This process is generated and perpetuated by several mechanisms that provide the disease with part of its malignancy potential and genetic and cytological characteristics. Disease pathological features are used for diagnosis and prognosis; however, most of them are obtained by a bone marrow aspirate, so it is crucial to find other less invasive methods to establish or complement the diagnosis, prognosis, and follow-up of the disease. A cancer biomarker is any measurable indicator demonstrating the presence of malignancy, tumor behavior, prognosis, or treatment responses. This review will summarize circulating diagnostic and prognosis biomarkers for B-cell progenitor ALL. Acute lymphoblastic leukemia (ALL) is a hematological disease characterized by the dysfunction of the hematopoietic system that leads to arrest at a specific stage of stem cells development, suppressing the average production of cellular hematologic components. BCP-ALL is a neoplasm of the B-cell lineage progenitor. BCP-ALL is caused and perpetuated by several mechanisms that provide the disease with its tumor potential and genetic and cytological characteristics. These pathological features are used for diagnosis and the prognostication of BCP-ALL. However, most of these paraclinical tools can only be obtained by bone marrow aspiration, which, as it is an invasive study, can delay the diagnosis and follow-up of the disease, in addition to the anesthetic risk it entails for pediatric patients. For this reason, it is crucial to find noninvasive and accessible ways to supply information concerning diagnosis, prognosis, and the monitoring of the disease, such as circulating biomarkers. In oncology, a biomarker is any measurable indicator that demonstrates the presence of malignancy, tumoral behavior, prognosis, or responses to treatments. This review summarizes circulating molecules associated with BCP-ALL with potential diagnostic value, classificatory capacity during monitoring specific clinic features of the disease, and/or capacity to identify each BCP-ALL stage regarding its evolution and outcome of the patients with BCP-ALL. In the same way, we provide and classify biomarkers that may be used in further studies focused on clinical approaches or therapeutic target identification for BCP-ALL. [ABSTRACT FROM AUTHOR]

Simple Summary: Endometrial cancer (EC) is one of the most common gynecological malignancies. Therefore, it is of great clinical importance to identify potential candidates for diagnostic and prognostic biomarkers in order to identify high-risk patients and obtain a more accurate prognosis in a timely manner. MicroRNAs (miRs) are small single-stranded RNAs that regulate gene expression and play a role in all steps of cancer development. The miRs expressed in endometrial tumor tissue are probably involved in cell proliferation and differentiation, apoptosis, and carcinogenesis. We reviewed the literature to identify potential miRs that may function as diagnostic, prognostic, or response to treatment markers in EC. In developed countries, endometrial cancer (EC) is one of the most common neoplasms of the female reproductive system. MicroRNAs (miRs) are a class of single-stranded noncoding RNA molecules with lengths of 19–25 nucleotides that bind to target messenger RNA (mRNA) to regulate post-transcriptional gene expression. Although there is a large amount of research focused on identifying miRs with a diagnostic, prognostic, or response to treatment capacity in EC, these studies differ in terms of experimental methodology, types of samples used, selection criteria, and results obtained. Hence, there is a large amount of heterogeneous information that makes it difficult to identify potential miR biomarkers. We aimed to summarize the current knowledge on miRs that have been shown to be the most suitable potential markers for EC. We searched PubMed and Google Scholar without date restrictions or filters. We described 138 miRs with potential diagnostic, prognostic, or treatment response potential in EC. Seven diagnostic panels showed higher sensitivity and specificity for the diagnosis of EC than individual miRs. We further identified miRs up- or downregulated depending on the FIGO stage, precursor lesions, and staging after surgery, which provides insight into which miRs are expressed chronologically depending on the disease stage and/or that are modulated depending on the tumor grade based on histopathological evaluation. [ABSTRACT FROM AUTHOR]